Results 1 to 10 of about 7,975 (151)

Beta 2 adrenergic receptor agonists as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) [PDF]

npj Metabolic Health and Disease
MASH is a leading cause of liver transplantation. Here, we investigated formoterol, a long-acting β2 adrenergic receptor agonist (LABA), in MASH. Mice treated with a high-fat diet (HFD) for sixteen weeks developed liver steatosis and were treated with ...
Brennan S. Winkler, Kristina M. Stayer, Abhinav K. Rao, Ehtesham Arif, Tsultrim T. Mendenhall, Kristy L. Thomas, Kylie R. Driggers, Xiaofeng Zuo, Wayne Fitzgibbon, Peifeng Deng, Yanhui Su, Yujing Dang, Marie Gerges, Daniel Kagan, Vishwajeeth Pasham, Bethany Wolf, Don C. Rockey, Jessica H. Hartman, Joshua H. Lipschutz   +18 more
doaj   +2 more sources

Targeting beta-2 adrenergic receptor attenuates schizophrenia-like behavioral effects induced by ketamine in mice: cAMP/PKA/BDNF-PEA-3 and RIM-1α signaling pathways involvement [PDF]

Saudi Pharmaceutical Journal
The interplay between cAMP/PKA and neuroplasticity involves intricate signaling pathways that are crucial for brain function and are frequently disrupted in schizophrenia.
Mohammed M. Heikal, Ahmed F. Mohamed, Nora O. Abdel Rasheed, Dalia M. El-Tanbouly, Noha N. Nassar   +4 more
doaj   +2 more sources

Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD [PDF]

Pulmonary Pharmacology and Therapeutics, 2011
In the present study, we examined whether there is a difference in the onset of bronchodilatation between formoterol/beclomethasone 12/200 μg Modulite and formoterol/budesonide 9/320 μg Turbuhaler in patients with COPD. We enrolled 28 patients with stable COPD.
Mario Cazzola, Franco Pasqua, Luigi Ferri   +2 more
exaly   +4 more sources

Stability of formoterol concentration in scalp hair of patients using maintenance formoterol therapy for asthma or COPD (INCTFISH) [PDF]

Frontiers in Pharmacology
IntroductionHair testing provides a non-invasive, objective method with a long (retrospective) surveillance window for assessing medication adherence.
E. Sportel, K. Wagelaar, M. Brusse-Keizer, M. Brusse-Keizer, J. van der Palen, J. van der Palen, H. van Veen, M. Wessels, J. van Boven, J. van Boven, D. Touw, D. Touw, K. Movig   +12 more
doaj   +2 more sources

Is It Really Feasible to Use Budesonide–Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Previous studies suggest that inhaled budesonide-formoterol used as needed could effectively reduce the severe exacerbation of mild persistent asthma.
Xiang Tong, Tao Liu, Zhenzhen Li, Sitong Liu, Hong Fan   +4 more
doaj   +1 more source

Both Acute and Consecutive Days of Formoterol Stimulation Influence Myogenic, Mitochondrial, and myomiR Gene Expression in Human Skeletal Muscle Cells

Muscles, 2023
Skeletal muscle physiology is regulated by microRNA that are localized within skeletal muscle (myomiRs). This study investigated how the expression of myomiRs and genes regulating skeletal muscle mass and myogenesis are influenced in response to acute ...
Ryan A. Gordon, Emily L. Zumbro, Gena D. Guerin, Matthew L. Sokoloski, Vic Ben-Ezra, Christopher S. Brower, Rhett B. Rigby, Anthony A. Duplanty   +7 more
doaj   +1 more source

Beclomethasone/formoterolversusbudesonide/formoterol combination therapy in asthma [PDF]

European Respiratory Journal, 2006
The present study was designed to compare the fixed combination of beclomethasone and formoterol in a hydrofluoroalkane Modulite® (Chiesi Farmaceutici, Parma, Italy) pressurised metered-dose inhaler (pMDI), with a combination of budesonide and formoterol administeredviaa Turbuhaler® (AstraZeneca, Lund, Sweden) dry powder inhaler (DPI).This was a phase ...
PAPI, Alberto, Paggiaro P. L., Nicolini G., Vignola A. M., Fabbri L. M., Inhaled Combination Asthma Treatment versus SYmbicort Study Group   +5 more
openaire   +5 more sources

Optimization of Bronchodilator Treatment in COPD: A Comparison of the Glycopyrrolate/Formoterol Combination vs. Formoterol Alone [PDF]

Kirkuk Journal of Medical Sciences
Background: Using a glycopyrrolate/formoterol combination to manage COPD patients is considered a new method. The objectives of this study are to evaluate the effectiveness of the glycopyrrolate/formoterol combination against formoterol alone in ...
Hiwa Saber, Ahmed Abdullah
doaj   +1 more source

Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD

Frontiers in Pharmacology, 2018
Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β2-agonist (LABA ...
Paolo Montuschi, Giuseppe Santini, Nadia Mores, Alessia Vignoli, Francesco Macagno, Rugia Shoreh, Leonardo Tenori, Gina Zini, Leonello Fuso, Chiara Mondino, Corrado Di Natale, Arnaldo D'Amico, Claudio Luchinat, Peter J. Barnes, Tim Higenbottam   +14 more
doaj   +1 more source

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma

BMC Pulmonary Medicine, 2019
Background and objective The dose-response relationship of inhaled corticosteroid (ICS)/fast-onset long acting beta agonist (LABA) reliever therapy has not been formally addressed.
Richard Beasley, James Harper, Grace Bird, Harriette Dunphy, Alex Semprini, Ian D. Pavord, Alberto Papi, Mark Weatherall   +7 more
doaj   +1 more source